Fifty years ago this summer, President Lyndon B. Johnson secured his place in history by signing into law the legislation that created Medicare and Medicaid. It was a landmark in the nation’s social and political development and an evolutionary leap for community pharmacy.
Congress, Medicare and industry stakeholders should strike the right balance to cut out fraud in the Medicare Part D drug program while preserving patient access to critical medications, the National Community Pharmacists Association stated in comments submitted in conjunction with a House Energy and Commerce subcommittee hearing Tuesday on the topic.
Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility.
With health reform and the shift to accountable, evidence-based medicine slowly but surely transforming the nation’s massive but troubled healthcare system, new moves are afoot in both the legislative and executive branches of government that will further elevate the role played by the nation’s 300,000 pharmacists.
Reps. Doug Collins, R-Ga., and Dave Loebsack, D-Iowa, introduced on Tuesday H.R. 5815 — the Generic Drug Pricing Fairness Act — which creates greater transparency in how PBMs reimburse pharmacies for generic prescription drugs under Medicare Part D, the military’s TRICARE program, and the Federal Employees Health Benefits Program.
In the wake of an Oct. 21 blogpost on Health Affairs, “The $500 Billion Medicare Slowdown: A Story About Part D,” Ralph Neas, president and CEO of the Generic Pharmacuetical Association, issued the following statement.